Lipids & Cardiovascular disease Effect of Intensive Lipid Lowering on Progression of Coronary Atherosclerosis: Evidence for an Early Benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Trial. Primary Prevention of Cardiovascular Disease With Atorvastatin in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre Randomised Placebo-Controlled Trial Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study INTERHEART: A Global Case-Control Study of Risk Factors for Acute Myocardial Infarction Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes Insulin Resistance and Cardiovascular Events With Low HDL Cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT) Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure [pdf] Blood pressure & Renal Function Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Type 2 Diabetes Treatment Commentary on the Results and Clinical Implications of the PROactive Study PROACTIVE STUDY: Pioglitazone Protects Against MI, Stroke, Death in High-Risk Type 2 Diabetics Combined Rosiglitazone & Fenofibrate treatment of Type 2 diabetes leads to improved control with less fluid retention Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Type 1 Diabetes Treatment Diabetes Control and Complications Trial (DCCT) Prevention of Diabetes DREAM Trial, Rosiglitazone in diabetes prevention [pdf] XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial